News & Updates

Finerenone significantly reduces albuminuria vs placebo and maintains a manageable safety profile in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) receiving background therapy with renin-angiotensin-aldosterone system inhibitors (RAASi), the phase III FINE-ONE trial has shown. These findings represent an important step forward since RAASi were introduced for renoprotection in T1D more than 30 years ago.

High consumption of red meat appears to increase the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), but only in men, particularly at intake levels ranging from 75 to 90 g/day, reveals a recent study.